We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen (AMGN) Parsabiv Gets Positive CHMP Opinion in EU
Read MoreHide Full Article
Amgen, Inc. (AMGN - Free Report) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for its secondary hyperparathyroidism (SHPT) candidate Parsabiv (etelcalcetide).
Amgen is looking to get Parsabiv approved in the EU for the treatment of secondary hyperparathyroidism in adult chronic kidney disease (CKD) patients on dialysis. Amgen had submitted the Marketing Authorisation Application for Parsabiv last September.
The marketing authorization and the positive CHMP opinion were based on encouraging data from three phase III trials, including two placebo-controlled trials in more than 1,000 patients, and a head-to-head study comparing Parsabiv to Sensipar. All the three trials met their primary endpoints.
We note that Parsabiv is also under review in the U.S. In August, Amgen received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for Parsabiv in the indication. The company is currently reviewing the letter and expects to meet with the agency later this year to discuss the next step.
Parsabiv became part of Amgen’s portfolio following its Jul 2012 acquisition of privately held KAI Pharmaceuticals.
SHPT, a chronic and serious condition, is estimated to affect two million individuals in the world who receive dialysis. Approximately 88% of dialysis patients and 79% of patients on hemodialysis are expected to develop SHPT.
In a separate press release, Amgen and partner UCB S. A. (UCBJF - Free Report) announced that data from the phase III FRAME study were published in the New England Journal of Medicine and were also presented at a medical meeting in Atlanta. Results from the FRAME study, which evaluated Amgen’s romosozumab for the treatment of postmenopausal women with osteoporosis, were announced this February. In July, Amgen and UCB submitted a Biologic License Application to the FDA seeking an approval in this indication based on the data from the study.
Amgen currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Geron Corporation (GERN - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . Both these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Amgen (AMGN) Parsabiv Gets Positive CHMP Opinion in EU
Amgen, Inc. (AMGN - Free Report) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion for its secondary hyperparathyroidism (SHPT) candidate Parsabiv (etelcalcetide).
Amgen is looking to get Parsabiv approved in the EU for the treatment of secondary hyperparathyroidism in adult chronic kidney disease (CKD) patients on dialysis. Amgen had submitted the Marketing Authorisation Application for Parsabiv last September.
The marketing authorization and the positive CHMP opinion were based on encouraging data from three phase III trials, including two placebo-controlled trials in more than 1,000 patients, and a head-to-head study comparing Parsabiv to Sensipar. All the three trials met their primary endpoints.
We note that Parsabiv is also under review in the U.S. In August, Amgen received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for Parsabiv in the indication. The company is currently reviewing the letter and expects to meet with the agency later this year to discuss the next step.
AMGEN INC Price and Consensus
AMGEN INC Price and Consensus | AMGEN INC Quote
Parsabiv became part of Amgen’s portfolio following its Jul 2012 acquisition of privately held KAI Pharmaceuticals.
SHPT, a chronic and serious condition, is estimated to affect two million individuals in the world who receive dialysis. Approximately 88% of dialysis patients and 79% of patients on hemodialysis are expected to develop SHPT.
In a separate press release, Amgen and partner UCB S. A. (UCBJF - Free Report) announced that data from the phase III FRAME study were published in the New England Journal of Medicine and were also presented at a medical meeting in Atlanta. Results from the FRAME study, which evaluated Amgen’s romosozumab for the treatment of postmenopausal women with osteoporosis, were announced this February. In July, Amgen and UCB submitted a Biologic License Application to the FDA seeking an approval in this indication based on the data from the study.
Amgen currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Geron Corporation (GERN - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . Both these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>